Cancer spreads through a multi-step process called metastasis, where cells break away from the original tumor, travel through the bloodstream or lymphatic system, and take root in a distant organ. This process, not the original tumor itself, is responsible for the vast majority of cancer deaths. Understanding each stage helps explain why some cancers stay contained for years while others become aggressive early.
How Cancer Cells Break Free
Normal cells in your organs are tightly locked together by junctions that hold them in place, almost like rivets connecting sheets of metal. Cancer cells that are about to spread undergo a transformation where those junctions dissolve. A key adhesion protein on the cell surface gets cleaved and degraded, and the cell loses its fixed orientation. Instead of sitting anchored among its neighbors, it reorganizes its internal scaffolding into a shape built for movement: elongated, with protruding edges that act like sensory extensions, feeling for a path forward.
This shift from a stationary cell to a mobile one is sometimes called an epithelial-to-mesenchymal transition. In practical terms, the cancer cell goes from behaving like a brick in a wall to behaving like a free-moving organism. It develops sheet-like and spike-like projections at its leading edge that pull it through surrounding tissue.
Breaking Through Surrounding Tissue
Tumors don’t just push their way through healthy tissue. They dissolve it. Cancer cells produce enzymes that chew through the dense network of proteins surrounding them, a structural mesh called the extracellular matrix. These enzymes break down collagen (the body’s most abundant structural protein), fibronectin, elastin, and other scaffolding molecules that hold tissues together.
Invasive cancer cells form specialized protrusions called invadopodia, essentially tiny drills on the cell surface that concentrate these enzymes right at the point of contact with the matrix. One particularly important enzyme accumulates at these protrusions and enables localized degradation during the process of entering and exiting blood vessels. This targeted destruction clears a path for the cancer cell to migrate through tissue it would otherwise never be able to penetrate.
Entering the Bloodstream or Lymph System
Once mobile, cancer cells need a highway to reach distant organs. They have two options: blood vessels or lymphatic vessels. The choice matters, and different cancers favor different routes.
Lymphatic vessels are structurally easier to enter. They lack the tight seals between cells that blood vessels have, and they’re missing the protective outer layers and basement membranes that reinforce blood vessel walls. This makes lymphatics inherently “leaky” compared to blood vessels, lowering the barrier for cancer cells to slip inside. The lymphatic system also moves fluid passively, with low mechanical force, which is gentler on fragile tumor cells. Carcinomas (cancers of the skin, organs, and glands) and melanomas tend to spread through lymph nodes more often than sarcomas (cancers of bone and soft tissue), though the reasons aren’t fully understood.
Blood vessels offer a faster, more direct route to distant organs, but the high-pressure flow inside them can actually help dislodge cells from the primary tumor in the first place. Either route can ultimately deliver cancer cells to the bloodstream, because lymphatic fluid eventually drains into veins near the collarbone. This is why cancer that first shows up in lymph nodes can later appear in distant organs like the lungs or liver.
Surviving the Journey
Traveling through the circulatory system is extremely dangerous for a cancer cell. The bloodstream subjects cells to shear forces, immune surveillance, and a lack of the structural support they’re accustomed to. The vast majority of cancer cells that enter circulation die. Estimates vary, but only a tiny fraction survive long enough to reach a distant organ and attempt to establish a new tumor.
Cells traveling through the lymphatic system face somewhat better odds. The low-shear, passive flow is less physically destructive. Lymphatic permeability may even allow clusters of cancer cells, not just individual ones, to travel together. These clusters, which retain adhesion molecules that keep them stuck to each other, may have a survival advantage over lone cells.
Why Certain Cancers Spread to Certain Organs
Cancer doesn’t spread randomly. Breast cancer preferentially spreads to bone, liver, lungs, and brain. Prostate cancer favors bone. Colon cancer often goes to the liver first. This pattern, sometimes called the “seed and soil” principle, reflects the idea that a cancer cell (the seed) can only grow where the organ environment (the soil) is compatible.
Bone, for example, releases chemical signals that actively attract breast and prostate cancer cells. A signaling molecule produced by bone marrow cells acts as a homing beacon, and breast and prostate cancer cells carry the matching receptor that lets them follow the signal. Prostate cancer cells also display a surface molecule that binds to a receptor found specifically on the blood vessel lining inside bone, giving them a docking mechanism that doesn’t exist in most other tissues. The bone environment further supports tumor growth through its unique chemistry: high calcium concentration, acidic conditions, and abundant growth factors stored in the bone matrix.
How Tumors Prepare Distant Organs in Advance
One of the more surprising discoveries in cancer biology is that primary tumors can prepare distant organs for metastasis before any cancer cell arrives there. Tumors release signaling molecules into the bloodstream that travel ahead and reshape the destination organ, creating what researchers call a pre-metastatic niche.
These signals recruit immune cells, particularly a type of white blood cell called neutrophils, to the future metastatic site. Once there, these neutrophils do two things that help incoming cancer cells: they support the tumor-initiating ability of cancer cells that eventually arrive, and they suppress the immune cells (specifically a type of T cell) that would normally destroy them. The primary tumor’s signals also stimulate cells at the distant site to produce fibronectin, a structural protein that creates a welcoming scaffold for arriving cancer cells.
In one striking example, pancreatic cancers release tiny vesicles that are taken up by immune cells in the liver, which then trigger liver cells to remodel the local tissue into a cancer-friendly environment. Breast cancers can secrete an enzyme that crosslinks collagen in the lungs, recruiting immune cells that further prepare the site. Some primary tumors even alter the metabolism of distant organs: breast cancer has been shown to reprogram lung and brain cells to increase local glucose availability, essentially stockpiling fuel for cancer cells that haven’t arrived yet.
How Cancer Cells Stay Hidden for Years
Not every cancer cell that reaches a distant organ starts growing immediately. Some enter a dormant state, pausing their growth cycle while remaining alive and metabolically active. These dormant cells can persist for years or even decades, which explains why some cancers recur long after apparently successful treatment.
Dormant cancer cells exit the active growth cycle and enter a resting phase. Specific proteins act as brakes on cell division, keeping the cells from proliferating. At the same time, these cells activate survival pathways that help them withstand the stress of their environment and even resist the effects of cancer therapies, which typically target actively dividing cells.
The immune system plays a direct role in maintaining dormancy. Killer T cells, natural killer cells, and signaling proteins called interferons actively suppress dormant cancer cells, keeping them in check. This creates a standoff: the cancer cells are alive but contained. If the immune system weakens, or if changes in the local environment tip the balance, dormant cells can reactivate and begin growing into a detectable metastasis. This is why a person treated for early-stage breast cancer, for example, can develop bone metastases five, ten, or even twenty years later.
Detecting Spreading Cancer Cells
Doctors can now look for evidence of spreading cancer through blood tests called liquid biopsies, which search for circulating tumor cells or fragments of tumor DNA floating in the bloodstream. These tests have generated significant interest because they’re far less invasive than traditional tissue biopsies.
In practice, the technology is still catching up to the promise. Only a handful of liquid biopsy tests have received FDA approval, and these are limited to specific uses: one captures circulating tumor cells in metastatic breast, prostate, and colorectal cancers, while others detect specific gene mutations to help guide treatment decisions. The broader challenge is sensitivity. Tumor DNA in the blood is extremely scarce, and current sequencing technology has an inherent error rate that makes it difficult to reliably detect mutations when they’re present at very low levels. Cross-platform consistency is also a concern, with poor agreement found between different commercial testing platforms when examining the same set of genes.
For now, liquid biopsies are most useful in specific clinical scenarios rather than as a general screening tool for metastasis. Standard imaging (CT scans, MRIs, bone scans, PET scans) remains the primary way doctors assess whether and where cancer has spread.